Perseus Proteomics（4882）株式概要ペルセウスプロテオミクス株式会社は、日本でがんやその他の疾患に対する抗体医薬を開発する創薬バイオベンチャー企業です。 詳細4882 ファンダメンタル分析スノーフレーク・スコア評価0/6将来の成長0/6過去の実績0/6財務の健全性6/6配当金0/6リスク分析収益が 100 万ドル未満 ( ¥136M )過去5年間で収益は年間8%減少しました。 意味のある時価総額がありません ( ¥3B )JP市場と比較した過去 3 か月間の株価の変動+1 さらなるリスクすべてのリスクチェックを見る4882 Community Fair Values Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.Your Fair ValueJP¥Current PriceJP¥170.00534.8% 割高 内在価値ディスカウントGrowth estimate overAnnual revenue growth rate5 Yearstime period%/yrDecreaseIncreasePastFuture-1b303m2016201920222025202620282031Revenue JP¥263.5mEarnings JP¥48.6mAdvancedSet Fair ValueView all narrativesPerseus Proteomics Inc. 競合他社Transgenic GroupSymbol: TSE:2342Market cap: JP¥3.5bD. Western Therapeutics InstituteSymbol: TSE:4576Market cap: JP¥4.0bKohjin BioSymbol: TSE:177AMarket cap: JP¥5.0bKidswell BioSymbol: TSE:4584Market cap: JP¥6.6b価格と性能株価の高値、安値、推移の概要Perseus Proteomics過去の株価現在の株価JP¥170.0052週高値JP¥432.0052週安値JP¥142.00ベータ0.321ヶ月の変化2.41%3ヶ月変化-29.75%1年変化-58.33%3年間の変化-40.35%5年間の変化-78.26%IPOからの変化-80.37%最新ニュースNew Risk • Jun 09New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 15% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 8.0% per year over the past 5 years. Revenue is less than US$1m (JP¥135m revenue, or US$844k). Minor Risks Share price has been volatile over the past 3 months (7.8% average weekly change). Shareholders have been diluted in the past year (15% increase in shares outstanding). Market cap is less than US$100m (JP¥2.52b market cap, or US$15.7m).Reported Earnings • May 19Full year 2026 earnings released: JP¥48.17 loss per share (vs JP¥63.35 loss in FY 2025)Full year 2026 results: JP¥48.17 loss per share (improved from JP¥63.35 loss in FY 2025). Revenue: JP¥135.0m (up 13% from FY 2025). Net loss: JP¥718.0m (loss narrowed 21% from FY 2025). Over the last 3 years on average, earnings per share has increased by 19% per year but the company’s share price has fallen by 14% per year, which means it is significantly lagging earnings.お知らせ • May 14Perseus Proteomics Inc., Annual General Meeting, Jun 24, 2026Perseus Proteomics Inc., Annual General Meeting, Jun 24, 2026.Reported Earnings • Feb 16Third quarter 2026 earnings released: JP¥11.39 loss per share (vs JP¥13.50 loss in 3Q 2025)Third quarter 2026 results: JP¥11.39 loss per share (improved from JP¥13.50 loss in 3Q 2025). Revenue: JP¥43.0m (up 82% from 3Q 2025). Net loss: JP¥168.0m (loss narrowed 16% from 3Q 2025). Over the last 3 years on average, earnings per share has increased by 13% per year but the company’s share price has fallen by 11% per year, which means it is significantly lagging earnings.お知らせ • Jan 05Perseus Proteomics Inc. announced that it has received ¥2.9808 million in funding from Macquarie Bank LimitedOn January 5, 2026, Perseus Proteomics Inc. closed the transaction.お知らせ • Dec 19Perseus Proteomics Inc. announced that it expects to receive ¥2.9808 million in funding from Macquarie Group LimitedPerseus Proteomics Inc. announced a private placement of 36,800 29th stock acquisition rights at ¥81 per stock acquisition right for gross proceeds of ¥2,980,800 on December 17, 2025. The transaction included participation from new investor Macquarie Group Limited. The potential shares from the issuance of stock acquisition rights will be 3,680,000 shares. The initial exercise price of stock acquisition rights ¥255 for a period from January 6, 2026 to January 5, 2028. The transaction will happen through third party allocation. The issue date for stock acquisition rights will be January 5, 2026. The transaction has been approved at board of directors’ meeting of the company.最新情報をもっと見るRecent updatesNew Risk • Jun 09New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 15% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 8.0% per year over the past 5 years. Revenue is less than US$1m (JP¥135m revenue, or US$844k). Minor Risks Share price has been volatile over the past 3 months (7.8% average weekly change). Shareholders have been diluted in the past year (15% increase in shares outstanding). Market cap is less than US$100m (JP¥2.52b market cap, or US$15.7m).Reported Earnings • May 19Full year 2026 earnings released: JP¥48.17 loss per share (vs JP¥63.35 loss in FY 2025)Full year 2026 results: JP¥48.17 loss per share (improved from JP¥63.35 loss in FY 2025). Revenue: JP¥135.0m (up 13% from FY 2025). Net loss: JP¥718.0m (loss narrowed 21% from FY 2025). Over the last 3 years on average, earnings per share has increased by 19% per year but the company’s share price has fallen by 14% per year, which means it is significantly lagging earnings.お知らせ • May 14Perseus Proteomics Inc., Annual General Meeting, Jun 24, 2026Perseus Proteomics Inc., Annual General Meeting, Jun 24, 2026.Reported Earnings • Feb 16Third quarter 2026 earnings released: JP¥11.39 loss per share (vs JP¥13.50 loss in 3Q 2025)Third quarter 2026 results: JP¥11.39 loss per share (improved from JP¥13.50 loss in 3Q 2025). Revenue: JP¥43.0m (up 82% from 3Q 2025). Net loss: JP¥168.0m (loss narrowed 16% from 3Q 2025). Over the last 3 years on average, earnings per share has increased by 13% per year but the company’s share price has fallen by 11% per year, which means it is significantly lagging earnings.お知らせ • Jan 05Perseus Proteomics Inc. announced that it has received ¥2.9808 million in funding from Macquarie Bank LimitedOn January 5, 2026, Perseus Proteomics Inc. closed the transaction.お知らせ • Dec 19Perseus Proteomics Inc. announced that it expects to receive ¥2.9808 million in funding from Macquarie Group LimitedPerseus Proteomics Inc. announced a private placement of 36,800 29th stock acquisition rights at ¥81 per stock acquisition right for gross proceeds of ¥2,980,800 on December 17, 2025. The transaction included participation from new investor Macquarie Group Limited. The potential shares from the issuance of stock acquisition rights will be 3,680,000 shares. The initial exercise price of stock acquisition rights ¥255 for a period from January 6, 2026 to January 5, 2028. The transaction will happen through third party allocation. The issue date for stock acquisition rights will be January 5, 2026. The transaction has been approved at board of directors’ meeting of the company.New Risk • Dec 18New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Japanese stocks, typically moving 5.5% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 14% per year over the past 5 years. Revenue is less than US$1m (JP¥121m revenue, or US$777k). Minor Risks Share price has been volatile over the past 3 months (5.5% average weekly change). Market cap is less than US$100m (JP¥3.91b market cap, or US$25.1m).分析記事 • Dec 17We're Not Very Worried About Perseus Proteomics' (TSE:4882) Cash Burn RateWe can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...お知らせ • Dec 12Perseus Proteomics Inc. to Report Q3, 2026 Results on Feb 13, 2026Perseus Proteomics Inc. announced that they will report Q3, 2026 results on Feb 13, 2026お知らせ • Sep 02Perseus Proteomics Inc. to Report Q2, 2026 Results on Nov 14, 2025Perseus Proteomics Inc. announced that they will report Q2, 2026 results on Nov 14, 2025Reported Earnings • Aug 16First quarter 2026 earnings released: JP¥11.93 loss per share (vs JP¥17.95 loss in 1Q 2025)First quarter 2026 results: JP¥11.93 loss per share (improved from JP¥17.95 loss in 1Q 2025). Net loss: JP¥176.0m (loss narrowed 29% from 1Q 2025). Over the last 3 years on average, earnings per share has fallen by 2% per year whereas the company’s share price has fallen by 4% per year.Board Change • Jul 01Insufficient new directorsThere is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 10 experienced directors. No highly experienced directors. Executive Officer, Head of R&D Dept., Head of Business Development Dept. and Director Shinji Hagiwara was the last director to join the board, commencing their role in 2023. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.お知らせ • Jun 27Perseus Proteomics Inc. to Report Q1, 2026 Results on Aug 14, 2025Perseus Proteomics Inc. announced that they will report Q1, 2026 results on Aug 14, 2025Reported Earnings • May 21Full year 2025 earnings released: JP¥63.35 loss per share (vs JP¥93.65 loss in FY 2024)Full year 2025 results: JP¥63.35 loss per share (improved from JP¥93.65 loss in FY 2024). Net loss: JP¥904.0m (loss narrowed 18% from FY 2024). Over the last 3 years on average, earnings per share has fallen by 8% per year but the company’s share price has only fallen by 1% per year, which means it has not declined as severely as earnings.お知らせ • May 15Perseus Proteomics Inc., Annual General Meeting, Jun 27, 2025Perseus Proteomics Inc., Annual General Meeting, Jun 27, 2025.お知らせ • Mar 18Perseus Proteomics Inc. Announces PPMX-T003 Notice on Completion of Clinical Study Report of Phase I Clinical Trial Among Polycythemia Vera PatientsPerseus Proteomics Inc. announced that it has completed the clinical study report (CSR) of the Phase I clinical trial of an anti-transferrin receptor 1 antibody, PPMX-T003 ("the Phase I"), among polycythemia vera ("PV") patients. The Phase I was conducted with six subjects suffering from PV, a disease characterized by abnormal increase in red blood cells to evaluate safety and pharmacokinetics of PPMX-T003, as well as to confirm its efficacy as secondary endpoints. As a result, no serious adverse events of concern regarding the safety of PPMX-T001 were confirmed and efficacy was indicated with RBC parameters including hematocrit and hemoglobin. Also, a 12-week period without the need for phlebotomy was achieved in 5 subjects except for the sixth subject whose tests were terminated due to personal reasons. There is no impact on the business result for the fiscal year 2025/3. There is no impact on The business result for the fiscal year 2022/3. There is no effect on the business result for the Fiscal year 2025/3.お知らせ • Mar 01Perseus Proteomics Inc. to Report Fiscal Year 2025 Results on May 15, 2025Perseus Proteomics Inc. announced that they will report fiscal year 2025 results on May 15, 2025Reported Earnings • Feb 16Third quarter 2025 earnings released: JP¥13.50 loss per share (vs JP¥22.57 loss in 3Q 2024)Third quarter 2025 results: JP¥13.50 loss per share (improved from JP¥22.57 loss in 3Q 2024). Net loss: JP¥199.0m (loss narrowed 25% from 3Q 2024). Over the last 3 years on average, earnings per share has fallen by 14% per year but the company’s share price has increased by 20% per year, which means it is well ahead of earnings.お知らせ • Jan 03Perseus Proteomics Inc. to Report Q3, 2025 Results on Feb 14, 2025Perseus Proteomics Inc. announced that they will report Q3, 2025 results on Feb 14, 2025分析記事 • Dec 13Here's Why We're Not Too Worried About Perseus Proteomics' (TSE:4882) Cash Burn SituationWe can readily understand why investors are attracted to unprofitable companies. For example, although...お知らせ • Dec 12Perseus Proteomics Inc. Announces Extension of Investigator-Led Phase I/II Clinical Trial for Aggressive NK-cell Leukemia (ANKL)Perseus Proteomics Inc. announced that the period of investigator-led phase I/II clinical trial of PPMX-T003, an anti-transferrin receptor 1 antibody, for aggressive NK-cell leukemia has been extended until March 31, 2026. Facing challenges in subject registration due to the target being an exceptionally rare disease, the Company has been preparing for the extension of the clinical trial with the clinical trial coordinators and other related parties. Recently, the clinical trial coordinator determined that it would be difficult to complete the study by March 31, 2025. Thus, an extension of the trial period until March 31, 2026 has been registered with the jRCT (Japan Registry of Clinical Trials), a system for submitting and publicizing clinical research. The Company is closely examining the impact on the business results of the fiscal year ending March, 2025 as well as the following fiscal year and will disclose the results immediately.お知らせ • Sep 27Perseus Proteomics Inc. Announces Registration of Patent Jointly Filed with Juntendo UniversityPerseus Proteomics Inc. announced that a patent has been registered in Japan regarding PPMX-T003, an anti-transferrin receptor 1 antibody. This patent was jointly filed with the research group of Chief Professor Norio Komatsu at Faculty of Medicine and Senior Associate Professor Marito Araki at Graduate School of Medicine, Juntendo University (affiliations were at the time of application). Title of invention: THERAPEUTIC DRUG FOR POLYCYTHEMIA. Patent No.: JPB7560815. Registration date: September 25, 2024. This patent stipulates therapeutic applications of PPMX-T003 for polycythemia vera, among other various applications. The Company and the university have filed applications for patents in other major countries as well. The Company has been striving for strengthening intellectual property rights for a broad range of therapeutic applications of PPMX-T003. Substance patents of this antibody have been already registered and plural applications are under examination. There is no impact on the financial results for the fiscal year ending March 31, 2025.お知らせ • Aug 27Perseus Proteomics Inc. to Report Q2, 2025 Results on Nov 14, 2024Perseus Proteomics Inc. announced that they will report Q2, 2025 results on Nov 14, 2024Reported Earnings • Aug 19First quarter 2025 earnings released: JP¥15.77 loss per share (vs JP¥35.89 loss in 1Q 2024)First quarter 2025 results: JP¥15.77 loss per share (improved from JP¥35.89 loss in 1Q 2024). Net loss: JP¥219.0m (loss narrowed 48% from 1Q 2024).Reported Earnings • Jun 25Full year 2024 earnings released: JP¥93.65 loss per share (vs JP¥66.84 loss in FY 2023)Full year 2024 results: JP¥93.65 loss per share (further deteriorated from JP¥66.84 loss in FY 2023). Net loss: JP¥1.10b (loss widened 41% from FY 2023). Over the last 3 years on average, earnings per share has fallen by 23% per year whereas the company’s share price has fallen by 21% per year.Reported Earnings • May 21Full year 2024 earnings released: JP¥93.65 loss per share (vs JP¥66.84 loss in FY 2023)Full year 2024 results: JP¥93.65 loss per share (further deteriorated from JP¥66.84 loss in FY 2023). Net loss: JP¥1.10b (loss widened 41% from FY 2023).お知らせ • May 17Perseus Proteomics Inc., Annual General Meeting, Jun 20, 2024Perseus Proteomics Inc., Annual General Meeting, Jun 20, 2024.お知らせ • May 11Perseus Proteomics Inc. Announces on Delay in the End of Phase I Clinical Trial for Polycythemia VeraPerseus Proteomics Inc. announced that there will be a delay in the end of the Phase I clinical trial of PPMX-T003, an anti-transferrin receptor 1 (TfR1) antibody, among PV patients from the previous forecast of the end of June 2024 to the end of July 2024. This trial primarily investigates the safety and pharmacokinetics in administering PPMX-T003 to 6 patients suffering from PV, a disease characterized by excess increase in red blood cells (RBCs). The secondary purpose is to confirm the therapeutic effects. The tests of the 5 patients have already ended and the company has continued the test of the remaining 1 patient. Due to the comprehensive judgement of a doctor considering the background unique to the patient, PPMX-T003 was administered at the increased dosage. The observation period is expected to finish in the end of July 2024. PPMX-T003 is an antibody targeting TfR1 that is related to iron intake into cells. TfR1 is highly expressed in cells that require much more iron than usual cells. Erythroblasts, which are nucleated cells in bone marrow from which RBCs derive, are one of them. When PPMX-T003 binds to TfR1, it inhibits cell proliferation by inhibiting iron uptake into erythroblasts. Therefore, it is expected to normalize the number of RBCs of PV patients, who have too many RBCs. TfR1 is also expressed in cancer cells that proliferate at a significant pace. PPMX-T003 similarly inhibits proliferation of cancer cells due to its function of inhibiting iron intake. Also, investigator-led phase I/II clinical trial of PPMX-T003 among aggressive NK-call leukemia (ANKL) patients is underway.New Risk • Apr 27New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 4.0% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (12% average weekly change). Earnings have declined by 22% per year over the past 5 years. Revenue is less than US$1m (JP¥96m revenue, or US$608k). Minor Risks Shareholders have been diluted in the past year (4.0% increase in shares outstanding). Market cap is less than US$100m (JP¥4.21b market cap, or US$26.6m).お知らせ • Mar 07Perseus Proteomics Inc. announced that it has received ¥1.566 million in funding from Barclays Bank PLC (Tokyo Branch)On March 7, 2024, Perseus Proteomics Inc. closed the transaction.お知らせ • Mar 02Perseus Proteomics Inc. to Report Fiscal Year 2024 Results on May 15, 2024Perseus Proteomics Inc. announced that they will report fiscal year 2024 results on May 15, 2024Reported Earnings • Feb 16Third quarter 2024 earnings releasedThird quarter 2024 results: Net loss: JP¥266.7m (loss widened 34% from 3Q 2023).お知らせ • Feb 02Perseus Proteomics Inc. Announces on Delay in the End of Phase I Clinical Trial for Polycythemia VeraPerseus Proteomics Inc. announced that there will be a delay in the end of the Phase I clinical trial of PPMX-T003, an anti-transferrin receptor 1 (TfR1) antibody, among PV patients from the initial forecast of within the fiscal year ending March 31, 2024 to the end of June 2024. This trial primarily investigates the safety and pharmacokinetics in administering PPMX-T003 to 6 patients suffering from PV, a disease characterized by excess increase in red blood cells (RBCs). The secondary purpose is to confirm the therapeutic effects. The tests of the 4 patients have already ended and the Company has continued incremental administration of PPMX-T003 to the remaining 2 patients and follow-up observation. Due to the circumstances of the tests at the end of January, the observation period is to delay from the initial forecast. To be more concrete, administration to one patient was postponed due to circumstances and administration of the increased dosage to the other was decided. This trial is estimated to finish at the end of June 2024.お知らせ • Nov 30Perseus Proteomics Inc. to Report Q3, 2024 Results on Feb 14, 2024Perseus Proteomics Inc. announced that they will report Q3, 2024 results on Feb 14, 2024Reported Earnings • Nov 14Second quarter 2024 earnings releasedSecond quarter 2024 results: Net loss: JP¥211.5m (loss widened 30% from 2Q 2023).お知らせ • Oct 21Perseus Proteomics Inc. Announces Completion of Patients Enrollment in Phase I Clinical Trial for Polycythemia Vera (PV)Per Perseus Proteomics Inc. announced that the Company has completed enrollment of 6 patients in PPMX-T003, an anti-transferrin receptor 1 (TfR1) antibody, Phase I clinical trial among PV patients. This trial primarily investigates the safety and pharmacokinetics in administering PPMX-T003 to patients suffering from PV, a disease that causes production of red blood cells (RBCs) at an abnormal level. The secondary purpose is to confirm the therapeutic effects. The Company will administer PPMX-T004 to the newly enrolled patients and will finish the phase I clinical trial within the fiscal year 2023. There is no impact on the financial results forecast for the fiscal year 2023. About PPMX-T003: PPMX-T003 is an antibody targeting TfR1 that is related to iron intake into cells. TfR1 is highly expressed in cells that require much more iron than usual cells. Erythroblasts, which are nucleated cells in bone marrow from which RBCs derive, are one of them. When PPMX-T003 binds to TfR1, it inhibits cell proliferation by inhibiting iron uptake into erythroblasts. Therefore, it is expected to normalize the number of RBCs of PV patients, who have too many RBCs. TfR1 is also expressed in cancer cells that proliferate at a significant pace. PPMX-T003 similarly inhibits proliferation of cancer cells due to its function of inhibiting iron intake. Also, investigator-led phase I/II clinical trial of PPMX-T003 among aggressive NK-call leukemia (ANKL) patients is underway.お知らせ • Oct 11Perseus Proteomics Inc. Announces Sales Launch of New Antibodies/ReagentsPerseus Proteomics Inc. announced the sales launch of new antibodies/reagents: Anti-mAQP4 antibody (for reproducing symptoms of neuromyelitis optica in animal experiments, etc.). Anti-DOTA antibody (for measuring DOTA-bound antibodies concentration in blood in animal experiments or clinical trials, etc.). Anti-DM1 antibodyfor measuring ADC concentration in blood in animal experiments or clinical trials, etc.). The company provided various antibodies/reagents for researchers at academia or companies throughout the world. The company will provide various services to support research activities of academia and companies.お知らせ • Sep 28Perseus Proteomics, Inc. Announces Provision of Antibody Research Support Service Through Single Cell Cloning TechnologyPerseus Proteomics Inc. announced that the Company has started to provide antibody research support service utilizing single cell cloning technology. The Company has been working on the antibody drug discovery through hybridoma technology and phage display technology, utilizing the unique phage library and the screening method. Now the Company has adopted single cell cloning technology as a new antibody obtaining method. The Company will not only utilize this technology in drug discovery business but also develop it as research support service for research and development by academia and companies. This service enables to obtain antibodies through isolating, screening, and selecting the cell that produces the target antibodies one by one without conventionally required processes including fusing cells and establishing libraries. The platform of the Company has been integrated with a high throughput device so that antibodies can be obtained speedily and efficiently. Also, this service is available for a wide variety of applications including analysis of single cell genes, retrieval of rare cells, and cell cloning after inserting genes. The impact on the fiscal year 2023 business results of the Company is minor. The Company will aim to provide various services to support research activities of academia and companies.お知らせ • Sep 23Perseus Proteomics Inc. Announces on Dosing of the First Patient in Phase I/II Clinical Trial for Aggressive NK-Cell LeukemiaPer Perseus Proteomics Inc. announced that the first patient has been dosed with PPMX-T003 in the Phase I/II investigator-led clinical trial for aggressive NK-cell leukemia (ANKL). This clinical trial has been prepared and performed under the support by AMED since April 2022 after adopted as Project Promoting Support for Drug Discovery Support Program for Orphan drug prior to the Designation. Its purpose is to assess the safety and tolerability in administering PPMX-T003 to ANKL patients, as well as efficacy and pharmacokinetics. ANKL is a rare refractory hematological malignancy, with a need to establish the effective standard treatment as soon as possible. PPMX-T003 is an antibody targeting transferrin receptor 1 (TfR1) that is related to iron intake into cells. TfR1 is highly expressed in hematopoietic cells that require much more iron than usual cells, as well as cancer cells. When PPMX-T003 binds to TfR1, it is expected to inhibit cancer cell proliferation by inhibiting iron uptake into cancer cells. The Company has been also conducting the phase I clinical trial of PPMX-T003 for polycythemia vera, where RBCs increase at an abnormal level.お知らせ • Sep 02Perseus Proteomics Inc. to Report Q2, 2024 Results on Nov 13, 2023Perseus Proteomics Inc. announced that they will report Q2, 2024 results on Nov 13, 2023Reported Earnings • Aug 16First quarter 2024 earnings released: JP¥35.89 loss per share (vs JP¥17.01 loss in 1Q 2023)First quarter 2024 results: JP¥35.89 loss per share (further deteriorated from JP¥17.01 loss in 1Q 2023). Net loss: JP¥422.0m (loss widened 111% from 1Q 2023).お知らせ • Jun 03Perseus Proteomics Inc. to Report Q1, 2024 Results on Aug 14, 2023Perseus Proteomics Inc. announced that they will report Q1, 2024 results on Aug 14, 2023お知らせ • May 30Perseus Proteomics Inc. Announces the Interim Report of Phase I Clinical Trial of PPMX-T003Perseus Proteomics Inc. announced that the interim report of phase I clinical trial of PPMX-T003, its anti-transferrin receptor antibody, among polycythemia vera ("PV") patients was presented at the 118th Japanese Society of Hematology Kinki Association Meeting in Osaka on May 29, 2023. This is the interim report of phase I study in 6 PV patients. The results of 3 patients were almost in line with the results of phase I study among healthy volunteers (5 cohorts, total 40) B) No serious adverse events were seen in all the three patients and the same level of safety was confirmed as that among healthy volunteers. In case 1 and case 3, PPMX-T003 was administered at a dose of 0.25mg/kg, while dose escalated from 0.25mg/kg., 0.4mg/kg, to 0.64mg/kg in case 2. Before the phase I study, the three patients had been treated with phlebotomy every 4 to 9 weeks respectively. The study finished with confirmation that there was no need for phlebotomy for 12 weeks after administration in the three patients. As hematocrit and hemoglobin both decreased, it was also confirmed that administration of PPMX-T001 has a reducing effect on erythroblasts and red blood cells just like healthy volunteers. The detailed data on safety and promising treatment efficacy data were reported as well. Thus, it was shown that PPMX-T003 has a possibility to be an effective therapeutic drug against PV, a disease characterized by an excessive number of red blood cells.Reported Earnings • May 13Full year 2023 earnings releasedFull year 2023 results: Net loss: JP¥787.0m (loss widened 31% from FY 2022).お知らせ • May 13Perseus Proteomics Inc., Annual General Meeting, Jun 23, 2023Perseus Proteomics Inc., Annual General Meeting, Jun 23, 2023.Reported Earnings • Feb 15Third quarter 2023 earnings released: JP¥16.92 loss per share (vs JP¥10.12 loss in 3Q 2022)Third quarter 2023 results: JP¥16.92 loss per share (further deteriorated from JP¥10.12 loss in 3Q 2022). Net loss: JP¥199.0m (loss widened 67% from 3Q 2022).お知らせ • Feb 14Perseus Proteomics Inc. Provides Consolidated Earnings Guidance for the Fiscal Year Ending March 31, 2023Perseus Proteomics Inc. provided consolidated earnings guidance for the Fiscal Year Ending March 31, 2023. For the period, the company expects net sales to be JPY 77 million, operating loss to be JPY 703 million, loss to be JPY 854 million, basic loss per share to be JPY 72.62.お知らせ • Feb 07Perseus Proteomics Inc. Announces Extension of Phase I Clinical Trial of PPMX-T003 among Polycythemia Vera PatientsPerseus Proteomics Inc. announced that it has extended the clinical trial period of a Phase I clinical trial of PPMX-T003 among polycythemia vera patients and that it now expects the completion of the Phase 1 in the fiscal year 2023 ending March 31, 2024, changed from the fiscal year 2022 ending March 31, 2023. This is because recruitment of the patients has delayed from the initial plan. Since the purpose of the Phase I is to evaluate safety, the Company has set PV patients who have using only phlebotomy as treatment, not anti-cancer drugs or other existing drugs, as participants in this Phase I. The number of such patients, however, is small. Besides, the Company has set several inclusion criteria such as low EPO (hormone to stimulate production of red blood cells) levels and PV diagnosis with significance on the WHO diagnostic criteria (performing bone marrow biopsy, etc.) at the same time. The Company, however, has found that such criteria do not reflect the clinical practice. For example, in several PV patients, high EPO levels are shown due to the influence of phlebotomy. Therefore, the Company has amended the inclusion criteria to promote recruitment of the patients. The Company has also been striving to add clinical trial locations: currently four locations have been registered. As a result, PPMX-T003 was administered to the first and second patients in August 2022, and to the third in February 2023. With regards to the remaining three patients, however, the administration timing is still unpredictable. Considering the circumstances, the Company has decided to extend the clinical trial period. So far, no major problem of safety has been reported from the three participants. The Company will aim at completion of the Phase I as early as possible through adding more clinical trial locations, which is already under a procedure. There is no impact on the business result forecasts for the fiscal year 2022. As for the fiscal year 2023, the Company is studying the impact carefully.お知らせ • Nov 27Perseus Proteomics Inc. to Report Q3, 2023 Results on Feb 13, 2023Perseus Proteomics Inc. announced that they will report Q3, 2023 results on Feb 13, 2023Reported Earnings • Nov 16Second quarter 2023 earnings released: JP¥13.86 loss per share (vs JP¥10.12 loss in 2Q 2022)Second quarter 2023 results: JP¥13.86 loss per share (further deteriorated from JP¥10.12 loss in 2Q 2022). Net loss: JP¥163.0m (loss widened 37% from 2Q 2022).Board Change • Nov 16No independent directorsThere are 5 new directors who have joined the board in the last 3 years. Of these new board members, none were independent directors. The company's board is composed of: No independent directors. 8 non-independent directors. Director Tatsuya Nagase was the last director to join the board, commencing their role in 2022. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Lack of board continuity.Reported Earnings • Nov 13Second quarter 2023 earnings released: JP¥13.86 loss per share (vs JP¥10.12 loss in 2Q 2022)Second quarter 2023 results: JP¥13.86 loss per share (further deteriorated from JP¥10.12 loss in 2Q 2022). Net loss: JP¥163.0m (loss widened 37% from 2Q 2022).お知らせ • Nov 12Perseus Proteomics Inc. Provides Earnings Guidance for the Year Ending March 31, 2023Perseus Proteomics Inc. provided earnings guidance for the year ending March 31, 2023. For the year, the company expects net sales of JPY 77 million, operating loss of JPY 703 million, loss of JPY 854 million or JPY 72.62 per basic share.お知らせ • Sep 02Perseus Proteomics Inc. to Report Q2, 2023 Results on Nov 11, 2022Perseus Proteomics Inc. announced that they will report Q2, 2023 results on Nov 11, 2022お知らせ • Aug 25Perseus Proteomics Inc. Announces First/Second Patients Dosed in Phase I Clinical Trial Among Polycythemia Vera (Pv) PatientsPerseus Proteomics Inc. announce the first and second patients have been dosed PPMX-T003 in the Phase I clinical trial among PV patients. This trial will primarily investigate the safety and pharmacokinetics in administering PPMX-T003 to patients with PV, a disease where red blood cells (RBCs) multiply at an abnormal level. The secondary purpose is to confirm the therapeutic effects. In the recruitment of PV patients, the Company has amended the inclusion criteria to be closer to the real- world clinical practice after consultation with the investigators at the medical institutions. The Company expects the phase I clinical trial finishes within this fiscal year, as it has been preparing for the addition of medical institutions.お知らせ • Aug 13Perseus Proteomics Inc. Provides Earnings Guidance for the Year Ending March 31, 2023Perseus Proteomics Inc. provided earnings guidance for the year ending March 31, 2023. For the year, the company expects net sales of JPY 77 million, operating loss of JPY 703 million, loss of JPY 854 million or JPY 72.62 per basic share.お知らせ • Jun 02Perseus Proteomics Inc. to Report Q1, 2023 Results on Aug 12, 2022Perseus Proteomics Inc. announced that they will report Q1, 2023 results on Aug 12, 2022お知らせ • May 14Perseus Proteomics Inc., Annual General Meeting, Jun 23, 2022Perseus Proteomics Inc., Annual General Meeting, Jun 23, 2022.Board Change • Apr 27No independent directorsThere are 6 new directors who have joined the board in the last 3 years. Of these new board members, none were independent directors. The company's board is composed of: No independent directors. 9 non-independent directors. Director Takashi Ohno was the last director to join the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Lack of board continuity.お知らせ • Apr 08Perseus Proteomics Inc. to Report Fiscal Year 2022 Results on May 13, 2022Perseus Proteomics Inc. announced that they will report fiscal year 2022 results on May 13, 2022お知らせ • Feb 16Perseus Proteomics Inc. Provides Earnings Guidance for the Year Ending March 31, 2022Perseus Proteomics Inc. provided earnings guidance for the year ending March 31, 2022. For the year, the company expects net sales of JPY 70 million, operating loss of JPY 564 million, loss of JPY 625 million or JPY 57.16 per basic share.お知らせ • Sep 15Perseus Proteomics Inc. Announces Initiation of Phase I Clinical Trial in Polycythemia Vera PatientsPerseus Proteomics Inc. announced the initiation of the Phase I clinical trial among polycythemia vera patients with regards to the pipeline PPMX-T003, an anti-transferrin receptor antibody. The purpose of this trial is to confirm the safety and pharmacokinetics in administering PPMX-T003 to patients suffering from PV, a disease where red blood cells (RBCs) multiply at an abnormal level. The Company submitted the clinical trial notification to the PMDA on May 31, 2021, which was approved following the investigation. The Company has signed a contract between one of the hospitals where this trial will be implemented and expects administration to PV patients after registration. PPMX-T003 is an antibody targeting transferrin receptor (TfR) that is related to iron intake into cells. TfR is highly expressed in cells that require much more iron than usual cells: erythroblasts, which are nucleated cells in bone marrow from which RBCs derive, are one of them. When PPMX-T003 binds to TfR, it inhibits cell proliferation by inhibiting iron uptake into erythroblasts. Therefore, it is expected to normalize the number of RBCs of PV patients, who have too many RBCs. TfR is also expressed in cancer cells that proliferate at a significant pace. PPMX-T003 similarly inhibits proliferation of cancer cells due to its function of inhibition of iron intake. As PPMX-T003 is expected to have therapeutic effects for a wide variety of cancers including acute myeloma leukemia (AML), its development has been the main focus of the Company.株主還元4882JP BiotechsJP 市場7D12.6%-4.2%-1.3%1Y-58.3%-35.6%43.0%株主還元を見る業界別リターン: 4882過去 1 年間で-35.6 % の収益を上げたJP Biotechs業界を下回りました。リターン対市場: 4882は、過去 1 年間で43 % のリターンを上げたJP市場を下回りました。価格変動Is 4882's price volatile compared to industry and market?4882 volatility4882 Average Weekly Movement8.1%Biotechs Industry Average Movement7.9%Market Average Movement4.4%10% most volatile stocks in JP Market9.3%10% least volatile stocks in JP Market2.2%安定した株価: 4882の株価は、 JP市場と比較して過去 3 か月間で変動しています。時間の経過による変動: 4882の weekly volatility ( 8% ) は過去 1 年間安定していますが、依然としてJPの株式の 75% よりも高くなっています。会社概要設立従業員CEO（最高経営責任者ウェブサイト200132Takuya Yokokawawww.ppmx.comペルセウスプロテオミクス株式会社は創薬バイオベンチャー企業として、がんをはじめとする疾患に対する抗体医薬の開発を国内で行っている。同社は、抗体探索活動、ハイブリドーマ抗体配列決定、抗体蛋白質生産、抗体研究受託からなる抗体研究支援活動、抗体製品の供給を行っている。製品パイプラインには、抗肝がん抗体PPMX-T001、抗がん剤PPMX-T002、成人T細胞治療薬PPMX-T003、抗体薬物複合体PPMX-T004などがある。ペルセウスプロテオミクス株式会社は、あすか製薬株式会社と新規抗体医薬および特定疾患領域治療薬の開発に関する共同研究契約を締結しています。ペルセウスプロテオミクス株式会社は2001年に設立され、東京に本社を置いています。もっと見るPerseus Proteomics Inc. 基礎のまとめPerseus Proteomics の収益と売上を時価総額と比較するとどうか。4882 基礎統計学時価総額JP¥2.89b収益（TTM）-JP¥718.11m売上高(TTM)JP¥135.51m21.3xP/Sレシオ-4.0xPER（株価収益率4882 は割高か？公正価値と評価分析を参照収益と収入最新の決算報告書（TTM）に基づく主な収益性統計4882 損益計算書（TTM）収益JP¥135.51m売上原価JP¥19.34m売上総利益JP¥116.16mその他の費用JP¥834.27m収益-JP¥718.11m直近の収益報告Mar 31, 2026次回決算日該当なし一株当たり利益（EPS）-42.24グロス・マージン85.73%純利益率-529.94%有利子負債／自己資本比率0%4882 の長期的なパフォーマンスは？過去の実績と比較を見るView Valuation企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/06/25 01:51終値2026/06/25 00:00収益2026/03/31年間収益2026/03/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレークこのレポートを生成するために使用した分析モデルの詳細は、当社の Github ページ でご覧いただけます。また、レポートの使い方に関する ガイド や YouTube の チュートリアル もご用意しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Perseus Proteomics Inc. 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。0
New Risk • Jun 09New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 15% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 8.0% per year over the past 5 years. Revenue is less than US$1m (JP¥135m revenue, or US$844k). Minor Risks Share price has been volatile over the past 3 months (7.8% average weekly change). Shareholders have been diluted in the past year (15% increase in shares outstanding). Market cap is less than US$100m (JP¥2.52b market cap, or US$15.7m).
Reported Earnings • May 19Full year 2026 earnings released: JP¥48.17 loss per share (vs JP¥63.35 loss in FY 2025)Full year 2026 results: JP¥48.17 loss per share (improved from JP¥63.35 loss in FY 2025). Revenue: JP¥135.0m (up 13% from FY 2025). Net loss: JP¥718.0m (loss narrowed 21% from FY 2025). Over the last 3 years on average, earnings per share has increased by 19% per year but the company’s share price has fallen by 14% per year, which means it is significantly lagging earnings.
お知らせ • May 14Perseus Proteomics Inc., Annual General Meeting, Jun 24, 2026Perseus Proteomics Inc., Annual General Meeting, Jun 24, 2026.
Reported Earnings • Feb 16Third quarter 2026 earnings released: JP¥11.39 loss per share (vs JP¥13.50 loss in 3Q 2025)Third quarter 2026 results: JP¥11.39 loss per share (improved from JP¥13.50 loss in 3Q 2025). Revenue: JP¥43.0m (up 82% from 3Q 2025). Net loss: JP¥168.0m (loss narrowed 16% from 3Q 2025). Over the last 3 years on average, earnings per share has increased by 13% per year but the company’s share price has fallen by 11% per year, which means it is significantly lagging earnings.
お知らせ • Jan 05Perseus Proteomics Inc. announced that it has received ¥2.9808 million in funding from Macquarie Bank LimitedOn January 5, 2026, Perseus Proteomics Inc. closed the transaction.
お知らせ • Dec 19Perseus Proteomics Inc. announced that it expects to receive ¥2.9808 million in funding from Macquarie Group LimitedPerseus Proteomics Inc. announced a private placement of 36,800 29th stock acquisition rights at ¥81 per stock acquisition right for gross proceeds of ¥2,980,800 on December 17, 2025. The transaction included participation from new investor Macquarie Group Limited. The potential shares from the issuance of stock acquisition rights will be 3,680,000 shares. The initial exercise price of stock acquisition rights ¥255 for a period from January 6, 2026 to January 5, 2028. The transaction will happen through third party allocation. The issue date for stock acquisition rights will be January 5, 2026. The transaction has been approved at board of directors’ meeting of the company.
New Risk • Jun 09New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 15% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 8.0% per year over the past 5 years. Revenue is less than US$1m (JP¥135m revenue, or US$844k). Minor Risks Share price has been volatile over the past 3 months (7.8% average weekly change). Shareholders have been diluted in the past year (15% increase in shares outstanding). Market cap is less than US$100m (JP¥2.52b market cap, or US$15.7m).
Reported Earnings • May 19Full year 2026 earnings released: JP¥48.17 loss per share (vs JP¥63.35 loss in FY 2025)Full year 2026 results: JP¥48.17 loss per share (improved from JP¥63.35 loss in FY 2025). Revenue: JP¥135.0m (up 13% from FY 2025). Net loss: JP¥718.0m (loss narrowed 21% from FY 2025). Over the last 3 years on average, earnings per share has increased by 19% per year but the company’s share price has fallen by 14% per year, which means it is significantly lagging earnings.
お知らせ • May 14Perseus Proteomics Inc., Annual General Meeting, Jun 24, 2026Perseus Proteomics Inc., Annual General Meeting, Jun 24, 2026.
Reported Earnings • Feb 16Third quarter 2026 earnings released: JP¥11.39 loss per share (vs JP¥13.50 loss in 3Q 2025)Third quarter 2026 results: JP¥11.39 loss per share (improved from JP¥13.50 loss in 3Q 2025). Revenue: JP¥43.0m (up 82% from 3Q 2025). Net loss: JP¥168.0m (loss narrowed 16% from 3Q 2025). Over the last 3 years on average, earnings per share has increased by 13% per year but the company’s share price has fallen by 11% per year, which means it is significantly lagging earnings.
お知らせ • Jan 05Perseus Proteomics Inc. announced that it has received ¥2.9808 million in funding from Macquarie Bank LimitedOn January 5, 2026, Perseus Proteomics Inc. closed the transaction.
お知らせ • Dec 19Perseus Proteomics Inc. announced that it expects to receive ¥2.9808 million in funding from Macquarie Group LimitedPerseus Proteomics Inc. announced a private placement of 36,800 29th stock acquisition rights at ¥81 per stock acquisition right for gross proceeds of ¥2,980,800 on December 17, 2025. The transaction included participation from new investor Macquarie Group Limited. The potential shares from the issuance of stock acquisition rights will be 3,680,000 shares. The initial exercise price of stock acquisition rights ¥255 for a period from January 6, 2026 to January 5, 2028. The transaction will happen through third party allocation. The issue date for stock acquisition rights will be January 5, 2026. The transaction has been approved at board of directors’ meeting of the company.
New Risk • Dec 18New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Japanese stocks, typically moving 5.5% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 14% per year over the past 5 years. Revenue is less than US$1m (JP¥121m revenue, or US$777k). Minor Risks Share price has been volatile over the past 3 months (5.5% average weekly change). Market cap is less than US$100m (JP¥3.91b market cap, or US$25.1m).
分析記事 • Dec 17We're Not Very Worried About Perseus Proteomics' (TSE:4882) Cash Burn RateWe can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...
お知らせ • Dec 12Perseus Proteomics Inc. to Report Q3, 2026 Results on Feb 13, 2026Perseus Proteomics Inc. announced that they will report Q3, 2026 results on Feb 13, 2026
お知らせ • Sep 02Perseus Proteomics Inc. to Report Q2, 2026 Results on Nov 14, 2025Perseus Proteomics Inc. announced that they will report Q2, 2026 results on Nov 14, 2025
Reported Earnings • Aug 16First quarter 2026 earnings released: JP¥11.93 loss per share (vs JP¥17.95 loss in 1Q 2025)First quarter 2026 results: JP¥11.93 loss per share (improved from JP¥17.95 loss in 1Q 2025). Net loss: JP¥176.0m (loss narrowed 29% from 1Q 2025). Over the last 3 years on average, earnings per share has fallen by 2% per year whereas the company’s share price has fallen by 4% per year.
Board Change • Jul 01Insufficient new directorsThere is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 10 experienced directors. No highly experienced directors. Executive Officer, Head of R&D Dept., Head of Business Development Dept. and Director Shinji Hagiwara was the last director to join the board, commencing their role in 2023. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
お知らせ • Jun 27Perseus Proteomics Inc. to Report Q1, 2026 Results on Aug 14, 2025Perseus Proteomics Inc. announced that they will report Q1, 2026 results on Aug 14, 2025
Reported Earnings • May 21Full year 2025 earnings released: JP¥63.35 loss per share (vs JP¥93.65 loss in FY 2024)Full year 2025 results: JP¥63.35 loss per share (improved from JP¥93.65 loss in FY 2024). Net loss: JP¥904.0m (loss narrowed 18% from FY 2024). Over the last 3 years on average, earnings per share has fallen by 8% per year but the company’s share price has only fallen by 1% per year, which means it has not declined as severely as earnings.
お知らせ • May 15Perseus Proteomics Inc., Annual General Meeting, Jun 27, 2025Perseus Proteomics Inc., Annual General Meeting, Jun 27, 2025.
お知らせ • Mar 18Perseus Proteomics Inc. Announces PPMX-T003 Notice on Completion of Clinical Study Report of Phase I Clinical Trial Among Polycythemia Vera PatientsPerseus Proteomics Inc. announced that it has completed the clinical study report (CSR) of the Phase I clinical trial of an anti-transferrin receptor 1 antibody, PPMX-T003 ("the Phase I"), among polycythemia vera ("PV") patients. The Phase I was conducted with six subjects suffering from PV, a disease characterized by abnormal increase in red blood cells to evaluate safety and pharmacokinetics of PPMX-T003, as well as to confirm its efficacy as secondary endpoints. As a result, no serious adverse events of concern regarding the safety of PPMX-T001 were confirmed and efficacy was indicated with RBC parameters including hematocrit and hemoglobin. Also, a 12-week period without the need for phlebotomy was achieved in 5 subjects except for the sixth subject whose tests were terminated due to personal reasons. There is no impact on the business result for the fiscal year 2025/3. There is no impact on The business result for the fiscal year 2022/3. There is no effect on the business result for the Fiscal year 2025/3.
お知らせ • Mar 01Perseus Proteomics Inc. to Report Fiscal Year 2025 Results on May 15, 2025Perseus Proteomics Inc. announced that they will report fiscal year 2025 results on May 15, 2025
Reported Earnings • Feb 16Third quarter 2025 earnings released: JP¥13.50 loss per share (vs JP¥22.57 loss in 3Q 2024)Third quarter 2025 results: JP¥13.50 loss per share (improved from JP¥22.57 loss in 3Q 2024). Net loss: JP¥199.0m (loss narrowed 25% from 3Q 2024). Over the last 3 years on average, earnings per share has fallen by 14% per year but the company’s share price has increased by 20% per year, which means it is well ahead of earnings.
お知らせ • Jan 03Perseus Proteomics Inc. to Report Q3, 2025 Results on Feb 14, 2025Perseus Proteomics Inc. announced that they will report Q3, 2025 results on Feb 14, 2025
分析記事 • Dec 13Here's Why We're Not Too Worried About Perseus Proteomics' (TSE:4882) Cash Burn SituationWe can readily understand why investors are attracted to unprofitable companies. For example, although...
お知らせ • Dec 12Perseus Proteomics Inc. Announces Extension of Investigator-Led Phase I/II Clinical Trial for Aggressive NK-cell Leukemia (ANKL)Perseus Proteomics Inc. announced that the period of investigator-led phase I/II clinical trial of PPMX-T003, an anti-transferrin receptor 1 antibody, for aggressive NK-cell leukemia has been extended until March 31, 2026. Facing challenges in subject registration due to the target being an exceptionally rare disease, the Company has been preparing for the extension of the clinical trial with the clinical trial coordinators and other related parties. Recently, the clinical trial coordinator determined that it would be difficult to complete the study by March 31, 2025. Thus, an extension of the trial period until March 31, 2026 has been registered with the jRCT (Japan Registry of Clinical Trials), a system for submitting and publicizing clinical research. The Company is closely examining the impact on the business results of the fiscal year ending March, 2025 as well as the following fiscal year and will disclose the results immediately.
お知らせ • Sep 27Perseus Proteomics Inc. Announces Registration of Patent Jointly Filed with Juntendo UniversityPerseus Proteomics Inc. announced that a patent has been registered in Japan regarding PPMX-T003, an anti-transferrin receptor 1 antibody. This patent was jointly filed with the research group of Chief Professor Norio Komatsu at Faculty of Medicine and Senior Associate Professor Marito Araki at Graduate School of Medicine, Juntendo University (affiliations were at the time of application). Title of invention: THERAPEUTIC DRUG FOR POLYCYTHEMIA. Patent No.: JPB7560815. Registration date: September 25, 2024. This patent stipulates therapeutic applications of PPMX-T003 for polycythemia vera, among other various applications. The Company and the university have filed applications for patents in other major countries as well. The Company has been striving for strengthening intellectual property rights for a broad range of therapeutic applications of PPMX-T003. Substance patents of this antibody have been already registered and plural applications are under examination. There is no impact on the financial results for the fiscal year ending March 31, 2025.
お知らせ • Aug 27Perseus Proteomics Inc. to Report Q2, 2025 Results on Nov 14, 2024Perseus Proteomics Inc. announced that they will report Q2, 2025 results on Nov 14, 2024
Reported Earnings • Aug 19First quarter 2025 earnings released: JP¥15.77 loss per share (vs JP¥35.89 loss in 1Q 2024)First quarter 2025 results: JP¥15.77 loss per share (improved from JP¥35.89 loss in 1Q 2024). Net loss: JP¥219.0m (loss narrowed 48% from 1Q 2024).
Reported Earnings • Jun 25Full year 2024 earnings released: JP¥93.65 loss per share (vs JP¥66.84 loss in FY 2023)Full year 2024 results: JP¥93.65 loss per share (further deteriorated from JP¥66.84 loss in FY 2023). Net loss: JP¥1.10b (loss widened 41% from FY 2023). Over the last 3 years on average, earnings per share has fallen by 23% per year whereas the company’s share price has fallen by 21% per year.
Reported Earnings • May 21Full year 2024 earnings released: JP¥93.65 loss per share (vs JP¥66.84 loss in FY 2023)Full year 2024 results: JP¥93.65 loss per share (further deteriorated from JP¥66.84 loss in FY 2023). Net loss: JP¥1.10b (loss widened 41% from FY 2023).
お知らせ • May 17Perseus Proteomics Inc., Annual General Meeting, Jun 20, 2024Perseus Proteomics Inc., Annual General Meeting, Jun 20, 2024.
お知らせ • May 11Perseus Proteomics Inc. Announces on Delay in the End of Phase I Clinical Trial for Polycythemia VeraPerseus Proteomics Inc. announced that there will be a delay in the end of the Phase I clinical trial of PPMX-T003, an anti-transferrin receptor 1 (TfR1) antibody, among PV patients from the previous forecast of the end of June 2024 to the end of July 2024. This trial primarily investigates the safety and pharmacokinetics in administering PPMX-T003 to 6 patients suffering from PV, a disease characterized by excess increase in red blood cells (RBCs). The secondary purpose is to confirm the therapeutic effects. The tests of the 5 patients have already ended and the company has continued the test of the remaining 1 patient. Due to the comprehensive judgement of a doctor considering the background unique to the patient, PPMX-T003 was administered at the increased dosage. The observation period is expected to finish in the end of July 2024. PPMX-T003 is an antibody targeting TfR1 that is related to iron intake into cells. TfR1 is highly expressed in cells that require much more iron than usual cells. Erythroblasts, which are nucleated cells in bone marrow from which RBCs derive, are one of them. When PPMX-T003 binds to TfR1, it inhibits cell proliferation by inhibiting iron uptake into erythroblasts. Therefore, it is expected to normalize the number of RBCs of PV patients, who have too many RBCs. TfR1 is also expressed in cancer cells that proliferate at a significant pace. PPMX-T003 similarly inhibits proliferation of cancer cells due to its function of inhibiting iron intake. Also, investigator-led phase I/II clinical trial of PPMX-T003 among aggressive NK-call leukemia (ANKL) patients is underway.
New Risk • Apr 27New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 4.0% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (12% average weekly change). Earnings have declined by 22% per year over the past 5 years. Revenue is less than US$1m (JP¥96m revenue, or US$608k). Minor Risks Shareholders have been diluted in the past year (4.0% increase in shares outstanding). Market cap is less than US$100m (JP¥4.21b market cap, or US$26.6m).
お知らせ • Mar 07Perseus Proteomics Inc. announced that it has received ¥1.566 million in funding from Barclays Bank PLC (Tokyo Branch)On March 7, 2024, Perseus Proteomics Inc. closed the transaction.
お知らせ • Mar 02Perseus Proteomics Inc. to Report Fiscal Year 2024 Results on May 15, 2024Perseus Proteomics Inc. announced that they will report fiscal year 2024 results on May 15, 2024
Reported Earnings • Feb 16Third quarter 2024 earnings releasedThird quarter 2024 results: Net loss: JP¥266.7m (loss widened 34% from 3Q 2023).
お知らせ • Feb 02Perseus Proteomics Inc. Announces on Delay in the End of Phase I Clinical Trial for Polycythemia VeraPerseus Proteomics Inc. announced that there will be a delay in the end of the Phase I clinical trial of PPMX-T003, an anti-transferrin receptor 1 (TfR1) antibody, among PV patients from the initial forecast of within the fiscal year ending March 31, 2024 to the end of June 2024. This trial primarily investigates the safety and pharmacokinetics in administering PPMX-T003 to 6 patients suffering from PV, a disease characterized by excess increase in red blood cells (RBCs). The secondary purpose is to confirm the therapeutic effects. The tests of the 4 patients have already ended and the Company has continued incremental administration of PPMX-T003 to the remaining 2 patients and follow-up observation. Due to the circumstances of the tests at the end of January, the observation period is to delay from the initial forecast. To be more concrete, administration to one patient was postponed due to circumstances and administration of the increased dosage to the other was decided. This trial is estimated to finish at the end of June 2024.
お知らせ • Nov 30Perseus Proteomics Inc. to Report Q3, 2024 Results on Feb 14, 2024Perseus Proteomics Inc. announced that they will report Q3, 2024 results on Feb 14, 2024
Reported Earnings • Nov 14Second quarter 2024 earnings releasedSecond quarter 2024 results: Net loss: JP¥211.5m (loss widened 30% from 2Q 2023).
お知らせ • Oct 21Perseus Proteomics Inc. Announces Completion of Patients Enrollment in Phase I Clinical Trial for Polycythemia Vera (PV)Per Perseus Proteomics Inc. announced that the Company has completed enrollment of 6 patients in PPMX-T003, an anti-transferrin receptor 1 (TfR1) antibody, Phase I clinical trial among PV patients. This trial primarily investigates the safety and pharmacokinetics in administering PPMX-T003 to patients suffering from PV, a disease that causes production of red blood cells (RBCs) at an abnormal level. The secondary purpose is to confirm the therapeutic effects. The Company will administer PPMX-T004 to the newly enrolled patients and will finish the phase I clinical trial within the fiscal year 2023. There is no impact on the financial results forecast for the fiscal year 2023. About PPMX-T003: PPMX-T003 is an antibody targeting TfR1 that is related to iron intake into cells. TfR1 is highly expressed in cells that require much more iron than usual cells. Erythroblasts, which are nucleated cells in bone marrow from which RBCs derive, are one of them. When PPMX-T003 binds to TfR1, it inhibits cell proliferation by inhibiting iron uptake into erythroblasts. Therefore, it is expected to normalize the number of RBCs of PV patients, who have too many RBCs. TfR1 is also expressed in cancer cells that proliferate at a significant pace. PPMX-T003 similarly inhibits proliferation of cancer cells due to its function of inhibiting iron intake. Also, investigator-led phase I/II clinical trial of PPMX-T003 among aggressive NK-call leukemia (ANKL) patients is underway.
お知らせ • Oct 11Perseus Proteomics Inc. Announces Sales Launch of New Antibodies/ReagentsPerseus Proteomics Inc. announced the sales launch of new antibodies/reagents: Anti-mAQP4 antibody (for reproducing symptoms of neuromyelitis optica in animal experiments, etc.). Anti-DOTA antibody (for measuring DOTA-bound antibodies concentration in blood in animal experiments or clinical trials, etc.). Anti-DM1 antibodyfor measuring ADC concentration in blood in animal experiments or clinical trials, etc.). The company provided various antibodies/reagents for researchers at academia or companies throughout the world. The company will provide various services to support research activities of academia and companies.
お知らせ • Sep 28Perseus Proteomics, Inc. Announces Provision of Antibody Research Support Service Through Single Cell Cloning TechnologyPerseus Proteomics Inc. announced that the Company has started to provide antibody research support service utilizing single cell cloning technology. The Company has been working on the antibody drug discovery through hybridoma technology and phage display technology, utilizing the unique phage library and the screening method. Now the Company has adopted single cell cloning technology as a new antibody obtaining method. The Company will not only utilize this technology in drug discovery business but also develop it as research support service for research and development by academia and companies. This service enables to obtain antibodies through isolating, screening, and selecting the cell that produces the target antibodies one by one without conventionally required processes including fusing cells and establishing libraries. The platform of the Company has been integrated with a high throughput device so that antibodies can be obtained speedily and efficiently. Also, this service is available for a wide variety of applications including analysis of single cell genes, retrieval of rare cells, and cell cloning after inserting genes. The impact on the fiscal year 2023 business results of the Company is minor. The Company will aim to provide various services to support research activities of academia and companies.
お知らせ • Sep 23Perseus Proteomics Inc. Announces on Dosing of the First Patient in Phase I/II Clinical Trial for Aggressive NK-Cell LeukemiaPer Perseus Proteomics Inc. announced that the first patient has been dosed with PPMX-T003 in the Phase I/II investigator-led clinical trial for aggressive NK-cell leukemia (ANKL). This clinical trial has been prepared and performed under the support by AMED since April 2022 after adopted as Project Promoting Support for Drug Discovery Support Program for Orphan drug prior to the Designation. Its purpose is to assess the safety and tolerability in administering PPMX-T003 to ANKL patients, as well as efficacy and pharmacokinetics. ANKL is a rare refractory hematological malignancy, with a need to establish the effective standard treatment as soon as possible. PPMX-T003 is an antibody targeting transferrin receptor 1 (TfR1) that is related to iron intake into cells. TfR1 is highly expressed in hematopoietic cells that require much more iron than usual cells, as well as cancer cells. When PPMX-T003 binds to TfR1, it is expected to inhibit cancer cell proliferation by inhibiting iron uptake into cancer cells. The Company has been also conducting the phase I clinical trial of PPMX-T003 for polycythemia vera, where RBCs increase at an abnormal level.
お知らせ • Sep 02Perseus Proteomics Inc. to Report Q2, 2024 Results on Nov 13, 2023Perseus Proteomics Inc. announced that they will report Q2, 2024 results on Nov 13, 2023
Reported Earnings • Aug 16First quarter 2024 earnings released: JP¥35.89 loss per share (vs JP¥17.01 loss in 1Q 2023)First quarter 2024 results: JP¥35.89 loss per share (further deteriorated from JP¥17.01 loss in 1Q 2023). Net loss: JP¥422.0m (loss widened 111% from 1Q 2023).
お知らせ • Jun 03Perseus Proteomics Inc. to Report Q1, 2024 Results on Aug 14, 2023Perseus Proteomics Inc. announced that they will report Q1, 2024 results on Aug 14, 2023
お知らせ • May 30Perseus Proteomics Inc. Announces the Interim Report of Phase I Clinical Trial of PPMX-T003Perseus Proteomics Inc. announced that the interim report of phase I clinical trial of PPMX-T003, its anti-transferrin receptor antibody, among polycythemia vera ("PV") patients was presented at the 118th Japanese Society of Hematology Kinki Association Meeting in Osaka on May 29, 2023. This is the interim report of phase I study in 6 PV patients. The results of 3 patients were almost in line with the results of phase I study among healthy volunteers (5 cohorts, total 40) B) No serious adverse events were seen in all the three patients and the same level of safety was confirmed as that among healthy volunteers. In case 1 and case 3, PPMX-T003 was administered at a dose of 0.25mg/kg, while dose escalated from 0.25mg/kg., 0.4mg/kg, to 0.64mg/kg in case 2. Before the phase I study, the three patients had been treated with phlebotomy every 4 to 9 weeks respectively. The study finished with confirmation that there was no need for phlebotomy for 12 weeks after administration in the three patients. As hematocrit and hemoglobin both decreased, it was also confirmed that administration of PPMX-T001 has a reducing effect on erythroblasts and red blood cells just like healthy volunteers. The detailed data on safety and promising treatment efficacy data were reported as well. Thus, it was shown that PPMX-T003 has a possibility to be an effective therapeutic drug against PV, a disease characterized by an excessive number of red blood cells.
Reported Earnings • May 13Full year 2023 earnings releasedFull year 2023 results: Net loss: JP¥787.0m (loss widened 31% from FY 2022).
お知らせ • May 13Perseus Proteomics Inc., Annual General Meeting, Jun 23, 2023Perseus Proteomics Inc., Annual General Meeting, Jun 23, 2023.
Reported Earnings • Feb 15Third quarter 2023 earnings released: JP¥16.92 loss per share (vs JP¥10.12 loss in 3Q 2022)Third quarter 2023 results: JP¥16.92 loss per share (further deteriorated from JP¥10.12 loss in 3Q 2022). Net loss: JP¥199.0m (loss widened 67% from 3Q 2022).
お知らせ • Feb 14Perseus Proteomics Inc. Provides Consolidated Earnings Guidance for the Fiscal Year Ending March 31, 2023Perseus Proteomics Inc. provided consolidated earnings guidance for the Fiscal Year Ending March 31, 2023. For the period, the company expects net sales to be JPY 77 million, operating loss to be JPY 703 million, loss to be JPY 854 million, basic loss per share to be JPY 72.62.
お知らせ • Feb 07Perseus Proteomics Inc. Announces Extension of Phase I Clinical Trial of PPMX-T003 among Polycythemia Vera PatientsPerseus Proteomics Inc. announced that it has extended the clinical trial period of a Phase I clinical trial of PPMX-T003 among polycythemia vera patients and that it now expects the completion of the Phase 1 in the fiscal year 2023 ending March 31, 2024, changed from the fiscal year 2022 ending March 31, 2023. This is because recruitment of the patients has delayed from the initial plan. Since the purpose of the Phase I is to evaluate safety, the Company has set PV patients who have using only phlebotomy as treatment, not anti-cancer drugs or other existing drugs, as participants in this Phase I. The number of such patients, however, is small. Besides, the Company has set several inclusion criteria such as low EPO (hormone to stimulate production of red blood cells) levels and PV diagnosis with significance on the WHO diagnostic criteria (performing bone marrow biopsy, etc.) at the same time. The Company, however, has found that such criteria do not reflect the clinical practice. For example, in several PV patients, high EPO levels are shown due to the influence of phlebotomy. Therefore, the Company has amended the inclusion criteria to promote recruitment of the patients. The Company has also been striving to add clinical trial locations: currently four locations have been registered. As a result, PPMX-T003 was administered to the first and second patients in August 2022, and to the third in February 2023. With regards to the remaining three patients, however, the administration timing is still unpredictable. Considering the circumstances, the Company has decided to extend the clinical trial period. So far, no major problem of safety has been reported from the three participants. The Company will aim at completion of the Phase I as early as possible through adding more clinical trial locations, which is already under a procedure. There is no impact on the business result forecasts for the fiscal year 2022. As for the fiscal year 2023, the Company is studying the impact carefully.
お知らせ • Nov 27Perseus Proteomics Inc. to Report Q3, 2023 Results on Feb 13, 2023Perseus Proteomics Inc. announced that they will report Q3, 2023 results on Feb 13, 2023
Reported Earnings • Nov 16Second quarter 2023 earnings released: JP¥13.86 loss per share (vs JP¥10.12 loss in 2Q 2022)Second quarter 2023 results: JP¥13.86 loss per share (further deteriorated from JP¥10.12 loss in 2Q 2022). Net loss: JP¥163.0m (loss widened 37% from 2Q 2022).
Board Change • Nov 16No independent directorsThere are 5 new directors who have joined the board in the last 3 years. Of these new board members, none were independent directors. The company's board is composed of: No independent directors. 8 non-independent directors. Director Tatsuya Nagase was the last director to join the board, commencing their role in 2022. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Lack of board continuity.
Reported Earnings • Nov 13Second quarter 2023 earnings released: JP¥13.86 loss per share (vs JP¥10.12 loss in 2Q 2022)Second quarter 2023 results: JP¥13.86 loss per share (further deteriorated from JP¥10.12 loss in 2Q 2022). Net loss: JP¥163.0m (loss widened 37% from 2Q 2022).
お知らせ • Nov 12Perseus Proteomics Inc. Provides Earnings Guidance for the Year Ending March 31, 2023Perseus Proteomics Inc. provided earnings guidance for the year ending March 31, 2023. For the year, the company expects net sales of JPY 77 million, operating loss of JPY 703 million, loss of JPY 854 million or JPY 72.62 per basic share.
お知らせ • Sep 02Perseus Proteomics Inc. to Report Q2, 2023 Results on Nov 11, 2022Perseus Proteomics Inc. announced that they will report Q2, 2023 results on Nov 11, 2022
お知らせ • Aug 25Perseus Proteomics Inc. Announces First/Second Patients Dosed in Phase I Clinical Trial Among Polycythemia Vera (Pv) PatientsPerseus Proteomics Inc. announce the first and second patients have been dosed PPMX-T003 in the Phase I clinical trial among PV patients. This trial will primarily investigate the safety and pharmacokinetics in administering PPMX-T003 to patients with PV, a disease where red blood cells (RBCs) multiply at an abnormal level. The secondary purpose is to confirm the therapeutic effects. In the recruitment of PV patients, the Company has amended the inclusion criteria to be closer to the real- world clinical practice after consultation with the investigators at the medical institutions. The Company expects the phase I clinical trial finishes within this fiscal year, as it has been preparing for the addition of medical institutions.
お知らせ • Aug 13Perseus Proteomics Inc. Provides Earnings Guidance for the Year Ending March 31, 2023Perseus Proteomics Inc. provided earnings guidance for the year ending March 31, 2023. For the year, the company expects net sales of JPY 77 million, operating loss of JPY 703 million, loss of JPY 854 million or JPY 72.62 per basic share.
お知らせ • Jun 02Perseus Proteomics Inc. to Report Q1, 2023 Results on Aug 12, 2022Perseus Proteomics Inc. announced that they will report Q1, 2023 results on Aug 12, 2022
お知らせ • May 14Perseus Proteomics Inc., Annual General Meeting, Jun 23, 2022Perseus Proteomics Inc., Annual General Meeting, Jun 23, 2022.
Board Change • Apr 27No independent directorsThere are 6 new directors who have joined the board in the last 3 years. Of these new board members, none were independent directors. The company's board is composed of: No independent directors. 9 non-independent directors. Director Takashi Ohno was the last director to join the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Lack of board continuity.
お知らせ • Apr 08Perseus Proteomics Inc. to Report Fiscal Year 2022 Results on May 13, 2022Perseus Proteomics Inc. announced that they will report fiscal year 2022 results on May 13, 2022
お知らせ • Feb 16Perseus Proteomics Inc. Provides Earnings Guidance for the Year Ending March 31, 2022Perseus Proteomics Inc. provided earnings guidance for the year ending March 31, 2022. For the year, the company expects net sales of JPY 70 million, operating loss of JPY 564 million, loss of JPY 625 million or JPY 57.16 per basic share.
お知らせ • Sep 15Perseus Proteomics Inc. Announces Initiation of Phase I Clinical Trial in Polycythemia Vera PatientsPerseus Proteomics Inc. announced the initiation of the Phase I clinical trial among polycythemia vera patients with regards to the pipeline PPMX-T003, an anti-transferrin receptor antibody. The purpose of this trial is to confirm the safety and pharmacokinetics in administering PPMX-T003 to patients suffering from PV, a disease where red blood cells (RBCs) multiply at an abnormal level. The Company submitted the clinical trial notification to the PMDA on May 31, 2021, which was approved following the investigation. The Company has signed a contract between one of the hospitals where this trial will be implemented and expects administration to PV patients after registration. PPMX-T003 is an antibody targeting transferrin receptor (TfR) that is related to iron intake into cells. TfR is highly expressed in cells that require much more iron than usual cells: erythroblasts, which are nucleated cells in bone marrow from which RBCs derive, are one of them. When PPMX-T003 binds to TfR, it inhibits cell proliferation by inhibiting iron uptake into erythroblasts. Therefore, it is expected to normalize the number of RBCs of PV patients, who have too many RBCs. TfR is also expressed in cancer cells that proliferate at a significant pace. PPMX-T003 similarly inhibits proliferation of cancer cells due to its function of inhibition of iron intake. As PPMX-T003 is expected to have therapeutic effects for a wide variety of cancers including acute myeloma leukemia (AML), its development has been the main focus of the Company.
